Search results
EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments
Pharmaceutical Technology via Yahoo Finance· 2 days agoPatients were assigned randomly to arm A (n=155) or arm B (n=147), with 25% and 29% having prior...
Symptoms of the KP.3 COVID Variant, the New Dominant Strain
Prevention via Yahoo News· 5 days agoAdalja, M.D., senior scholar at the Johns ...drug that is designed for people who have...
Regeneron touts success with bispecific antibody in multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 6 days agoIn an interview with Clinical Trials Arena, Suzanne Lentzsch, a trial investigator, highlighted that...
Cessation to launch Phase IIa monoclonal antibody trial in opioid abuse
Clinical Trials Arena via Yahoo Finance· 3 days agoCSX-1004, especially secondary to its exceptionally long half-life, has the potential to supply...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 4 days agoEarlier this month, AbbVie in-licensed exclusive global rights to develop and commercialize FG-M701,...
'A totally new kid': Parents push for coverage of controversial IV treatment for brain condition
Detroit News· 4 days agoThe Grosse Pointe Park child was diagnosed with a brain condition known as PANS, Pediatric...
A Potential Parkinson's Treatment Has Promising Results
Time via Yahoo News· 3 days agoScientists then use a fluorescent probe to detect how much antibody to the misfolded protein...
COVID-19 is surging. Time to mask up or get a booster? What a Boise medical expert says
Idaho Statesman McClatchy via AOL· 2 days agoPeople 65 and older should get an additional dose 4 months after the previous one, according to the...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 4 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Treatment of Blood Cancers
Digital Journal· 5 days ago(NYSE American: ATNM). Actinium is a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies. Approximately every 3 minutes, one ...
